These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 7633019)

  • 1. Torsemide: a pyridine-sulfonylurea loop diuretic.
    Blose JS; Adams KF; Patterson JH
    Ann Pharmacother; 1995 Apr; 29(4):396-402. PubMed ID: 7633019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torsemide: a new loop diuretic.
    Fowler SF; Murray KM
    Am J Health Syst Pharm; 1995 Aug; 52(16):1771-80; quiz 1814-5. PubMed ID: 8528833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of the loop diuretics: should furosemide be first line?
    Wargo KA; Banta WM
    Ann Pharmacother; 2009 Nov; 43(11):1836-47. PubMed ID: 19843838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacodynamics of torsemide in patients with congestive heart failure.
    Vargo D; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1994 Jul; 56(1):48-54. PubMed ID: 8033494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torasemide for the treatment of heart failure.
    Ishido H; Senzaki H
    Cardiovasc Hematol Disord Drug Targets; 2008 Jun; 8(2):127-32. PubMed ID: 18537599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure.
    Gottlieb SS; Khatta M; Wentworth D; Roffman D; Fisher ML; Kramer WG
    Am J Med; 1998 Jun; 104(6):533-8. PubMed ID: 9674715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of torasemide in health and disease.
    Brater DC
    J Cardiovasc Pharmacol; 1993; 22 Suppl 3():S24-31. PubMed ID: 7506334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease.
    Peddle GD; Singletary GE; Reynolds CA; Trafny DJ; Machen MC; Oyama MA
    J Vet Cardiol; 2012 Mar; 14(1):253-9. PubMed ID: 22364690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency.
    Rudy DW; Gehr TW; Matzke GR; Kramer WG; Sica DA; Brater DC
    Clin Pharmacol Ther; 1994 Jul; 56(1):39-47. PubMed ID: 8033493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral administration of furosemide and torsemide in healthy dogs.
    Hori Y; Takusagawa F; Ikadai H; Uechi M; Hoshi F; Higuchi S
    Am J Vet Res; 2007 Oct; 68(10):1058-63. PubMed ID: 17916010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency.
    Gehr TW; Rudy DW; Matzke GR; Kramer WG; Sica DA; Brater DC
    Clin Pharmacol Ther; 1994 Jul; 56(1):31-8. PubMed ID: 8033492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics.
    Sica DA
    Congest Heart Fail; 2003; 9(5):287-92. PubMed ID: 14564148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
    Gentilini P; La Villa G; Marra F; Carloni V; Melani L; Foschi M; Cotrozzi G; Quartini M; Chibbaro G; Tommasi AC; Bernareggi A; Simoni A; Buzzelli G; Laffi G
    J Hepatol; 1996 Oct; 25(4):481-90. PubMed ID: 8912147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Torasemide. A review of its pharmacological properties and therapeutic potential.
    Friedel HA; Buckley MM
    Drugs; 1991 Jan; 41(1):81-103. PubMed ID: 1706990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure.
    Liguori A; Casini A; Di Loreto M; Andreini I; Napoli C
    Eur J Clin Pharmacol; 1999 Apr; 55(2):117-24. PubMed ID: 10335906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Torasemide (LUPRAC): a review of its pharmacological and clinical profile].
    Kido H; Ohtaki Y
    Nihon Yakurigaku Zasshi; 2001 Aug; 118(2):97-105. PubMed ID: 11530685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis.
    Schwartz S; Brater DC; Pound D; Green PK; Kramer WG; Rudy D
    Clin Pharmacol Ther; 1993 Jul; 54(1):90-7. PubMed ID: 8330470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Torsemide and Combination of Loop Diuretics Improve Mortality in Patients with Chronic Heart Failure After Discharge?
    Yao Y; Zhang J; Zhang Y; Zhang R
    Int Heart J; 2018 Jul; 59(4):813-820. PubMed ID: 29877310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torasemide. An update of its pharmacological properties and therapeutic efficacy.
    Dunn CJ; Fitton A; Brogden RN
    Drugs; 1995 Jan; 49(1):121-42. PubMed ID: 7705212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.